This article is more than 5 years old. Information may no longer be current.
Steroid therapy may provide stable, durable benefits to 5 years in diabetic macular edema patients
Ophthalmology. 2009;116(11):2182-2187.
Click Here to Manage Email Alerts
Intravitreal steroid therapy proved durable out to 5 years in patients treated for vision loss secondary to diabetic macular edema and benefited patients who were initially treated with placebo in the first 2 years of a study.
After 5 years of therapy, patients who received intravitreal injections of triamcinolone acetonide for the duration of the study had a mean visual acuity of 61.0 logMAR compared with 59.0 logMAR at baseline and 64.4 logMAR at 2 years.
In patients treated initially with placebo, visual acuity was similar at baseline, mean 59.5 logMAR, and after 2 years, mean 59.0 logMAR. However, after being crossed over to triamcinolone, visual acuity improved to a mean 61.2 logMAR at 5 years.
Patients in the study also received adjunctive laser therapy at baseline when appropriate, and investigators were permitted to offer laser therapy during follow-up.
Patients initially treated with triamcinolone received more injections during years 3 to 5 (43 injections in 16 patients) compared with the initial-placebo group (26 injections in 13 patients), but the difference was not statistically significant.
Foveal thickness decreased by 30 µm less in the initial-triamcinolone group compared with the initial-placebo group from baseline to year 5. From year 2 to year 5, central macular thickness increased slightly in the initial-triamcinolone group but decreased in the initial-placebo group.